Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Clinical Trial
Official title:
Comparison of Non-invasive Oxygenation Strategies in ICU Patients Admitted for Covid-19 Acute Respiratory Distress Syndrome
Acute Respiratory Distress Syndrome (ARDS) is the main clinical presentation of SARS-CoV-2 (Covid-19) infected patients admitted in Intensive Care Unit (ICU). During the first phase of the outbreak (between February and May 2020), the use of invasive Mechanical Ventilation (MV) was largely required with 63% of ICU patients intubated in the first 24 hours after admission and up to 80% of patients during the overall ICU stay. Mortality was especially higher when using MV in the first 24 hours. In contrast, the use of non-invasive oxygenation strategies in the first 24 hours was only 19% for High Flow Nasal Cannula oxygen therapy (HFNC) and 6% for Non-Invasive Ventilation (NIV). Several non-invasive oxygenation strategies were proposed in order to delay or avoid MV in ICU patients suffering from Covid-19 ARDS. The use of HFNC became the recommended oxygenation strategy, based in particular on publications prior to the outbreak. The use of NIV or Continuous Positive Airway Pressure (CPAP) combined with HFNC have also been proposed. Although these non-invasive oxygenation strategies seem widely used in the second phase of the outbreak, they have not yet confirmed their clinical impact on MV requirement and patient's outcome. Moreover, no comparison has been made between these different non-invasive oxygenation strategies. The aim of this study is to compare different non-invasive oxygenation strategies (HFNC, NIV, CPAP) on MV requirement and outcome in ICU patients treated for ARDS related to Covid-19.
Retrospective multicenter observational registry in French intensive care unit including all consecutive patients admitted for acute respiratory distress syndrome related to SARS-CoV-2 pneumonia between1st July and 31th December 2020. Patients characteristics, ICU treatments and outcome will be recorded. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04768998 -
Intersectoral Platform (SÜP) of the National Pandemic Cohort Network (NAPKON)
|
||
| Terminated |
NCT04642638 -
Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure
|
Phase 2/Phase 3 | |
| Terminated |
NCT04940871 -
Study to Assess the Efficacy and Safety of Favipiravir-HU
|
Phase 2 | |
| Completed |
NCT04588363 -
COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-C
|
||
| Completed |
NCT05249816 -
Phase 3 Boosting Study for the SARS-CoV-2 rS Vaccine
|
Phase 3 | |
| Recruiting |
NCT04863547 -
Severity of the New UK SARS-Cov2 Variant in COVID-19 Infection
|
||
| Terminated |
NCT04389840 -
Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure
|
Phase 2/Phase 3 | |
| Completed |
NCT04933929 -
Personalized Dietary Advice 3 Months After Discharge From Hospitalization in Geriatrics: Effect on Nutritional Status According to Coronavirus Disease 2019 (COVID-19) Status (Positive or Negative) During Hospitalization
|
N/A | |
| Completed |
NCT04851821 -
The Effectiveness of Phytotherapy in SARS-COV2(COVID-19)
|
Phase 1 | |
| Withdrawn |
NCT05545319 -
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19
|
Phase 2 | |
| Terminated |
NCT04391309 -
COVID-19 and Anti-CD14 Treatment Trial
|
Phase 2 | |
| Completed |
NCT04343261 -
Convalescent Plasma in the Treatment of COVID 19
|
Phase 2 |